1. Stem Cell/Wnt
  2. Wnt


Cat. No.: HY-14428 Purity: 99.61%
Handling Instructions

ICG-001 is an antagonist of Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 μM.

For research use only. We do not sell to patients.
ICG-001 Chemical Structure

ICG-001 Chemical Structure

CAS No. : 847591-62-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 87 In-stock
5 mg USD 72 In-stock
10 mg USD 120 In-stock
50 mg USD 420 In-stock
100 mg USD 660 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    ICG-001 purchased from MCE. Usage Cited in: Cancer Sci. 2016 Dec;107(12):1776-1784.

    The amount of ABCC3 protein is increased by ICG-001 treatment in HT-29 cells.

    ICG-001 purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2017 Sep 11;36(1):125.

    ICG-001 mediates the association of β-catenin with CBP, P300, E-cadherin and N-cadherin. a and b Western blotting analysis of Wnt related proteins from total proteins and extracted nuclear and cytoplasmic proteins.

    ICG-001 purchased from MCE. Usage Cited in: Oncotarget. 2017 Dec 1;8(70):115089-115101.

    ICG001 depresses the heat-induced over-expression of EMT markers (N-cadherin, Snail), and partially recovers the expression of E-cadherin in heat-treated SUM-1315 and ZR-75-1 cells.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    ICG-001 is an antagonist of Wnt/β-catenin/TCF-mediated transcription and specifically binds to element-binding protein (CBP) with IC50 of 3 μM.

    IC50 & Target

    IC50: 3 μM (CBP)

    In Vitro

    ICG-001 (5μM) inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells[1]. ICG-001 can phenotypically rescue normal nerve growth factor (NGF)-induced neuronal differentiation and neurite outgrowth in the presenilin-1 mutant cells, emphasizing the importance of the TCF/β-catenin signaling pathway on neurite outgrowth and neuronal differentiation[2]. ICG-001 (25μM) treatment reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein in SW480 cells, both of which can be up-regulated by β-catenin. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, and reduces in vitro growth of colon carcinoma cells[3].

    In Vivo

    ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling and attenuates bleomycin-induced lung fibrosis in mice, while concurrently preserving the epithelium[2]. Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent Sulindac, which has consistently demonstrated efficacy in this model. ICG-001 (150 mg/kg, i.v.) demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss in the SW620 nude mouse xenograft model of tumor regression[3].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.8227 mL 9.1136 mL 18.2272 mL
    5 mM 0.3645 mL 1.8227 mL 3.6454 mL
    10 mM 0.1823 mL 0.9114 mL 1.8227 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    ICG-001 is dissolved in DMSO.

    To evaluate effects of ICG-001 on α-SMA and collagen type 1 expression, RLE-6TN cells are treated with TGF-β1 (0.25 ng/mL) in the presence or absence of ICG-001 (5.0 μM). After 24 h, cells are harvested and mRNA isolated for analysis by qPCR. RNA is reverse-transcribed using SuperScript reverse transcriptase. Quantitative PCR is performed with SYBR-Green PCR using Real-Time PCR System HT7900. The amplification protocol is set as follows: 95°C denaturation for 10 min followed by 40 cycles of 15-s denaturation at 95°C, 1 min of annealing/extension, and data collection at 60°C. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    ICG-001 is formulated in 1% carboxymethylcellulose.

    Seven-week-old male C57BL/6J-ApcMin/+and WT C57BL/6J mice are treated orally for 9 weeks with ICG-001a (300 mg/kg per day) or vehicle (1% carboxymethylcellulose), once daily, six times per week. Sulindac is administered in drinking water (160 ppm, dissolved in 8 mM Na2PO4 buffer, pH 7.6). At 16 weeks, the polyp number is counted manually by using a dissecting microscope. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    O=C(NCC1=CC=CC=C1)N2CCC(N([[email protected]@]2(CN(C3=O)CC4=C5C=CC=CC5=CC=C4)[H])[[email protected]]3CC6=CC=C(C=C6)O)=O

    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    ICG-001 is prepared in vehicle (PBS)[4].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.


    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: